STOCK TITAN

ADMA Biologics, Inc. - $ADMA STOCK NEWS

Welcome to our dedicated page for ADMA Biologics news (Ticker: $ADMA), a resource for investors and traders seeking the latest updates and insights on ADMA Biologics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ADMA Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ADMA Biologics's position in the market.

Rhea-AI Summary

ADMA Biologics reported impressive first quarter 2024 financial results, with a total revenue of $81.9 million, a 44% increase year-over-year. The GAAP net income was $17.8 million, a $24.6 million increase year-over-year. Adjusted EBITDA for Q1 2024 was $26.4 million, a 970% increase year-over-year. The company raised its total revenue guidance for FY 2024 to more than $355 million and for FY 2025 to more than $410 million. Net income guidance was also increased for both years, as well as Adjusted EBITDA guidance. ADMA highlighted the success of its ASCENIV™ and BIVIGAM® products in driving commercial growth and reaffirmed its commitment to immune deficient patients. The company is focused on advancing growth initiatives, including biologics production processes and preclinical pipeline programs, to exceed expectations and deliver value to stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.13%
Tags
-
Rhea-AI Summary

ADMA Biologics, Inc. (Nasdaq: ADMA) will report its first quarter 2024 financial results on May 9, 2024. The live conference call and audio webcast will be hosted by the management team at 4:30 p.m. ET on the same day to discuss the financial results and Company updates. Participants can register for the call to receive the dial-in numbers and unique PIN. An archived replay will be available on the Company's investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences earnings
-
Rhea-AI Summary
ADMA Biologics, Inc. receives FDA approval for extended room temperature storage conditions for ASCENIV and BIVIGAM, enhancing inventory management and product availability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
Rhea-AI Summary
ADMA Biologics, Inc. announces CEO's participation in Raymond James Institutional Investor Conference. The event will be live-streamed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
conferences
-
News
Rhea-AI Summary
ADMA Biologics, Inc. announced the transition of Brian Lenz, the current CFO, to a consulting role effective April 1, 2024. Lenz has been with the company for 11 years and played a crucial role in its growth and profitability. The company has appointed Adam Grossman as the Interim CFO and initiated an executive search for a permanent replacement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
Rhea-AI Summary
ADMA Biologics, Inc. reports strong financial performance for 4Q 2023 and FY 2023 with total revenue of $73.9 million and $258.2 million, respectively. Adjusted EBITDA for 4Q 2023 was $18.6 million, and FY 2023 was $40.3 million. The company increased its total revenue guidance for FY 2024 and 2025 to more than $330 million and $380 million, respectively. Net income guidance for FY 2024 and 2025 was also raised to more than $65 million and $115 million, respectively. ADMA is focusing on innovative growth opportunities, including manufacturing enhancements and a new pipeline for Hyperimmune Globulin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
Rhea-AI Summary
ADMA Biologics, Inc. (ADMA) will report its fourth quarter and full year 2023 financial results on February 28, 2024. The company will host a conference call to discuss the results and provide updates on the same day at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences earnings
-
Rhea-AI Summary
ADMA Biologics, Inc. successfully implements ADMAlytics, an AI program combining AI and machine learning to optimize production processes. The company achieved efficiency improvements in commercial production through automation, with broader implementation expected to enhance efficiencies across the organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
AI
-
Rhea-AI Summary
ADMA Biologics, Inc. (Nasdaq: ADMA) reported preliminary unaudited total revenue of $72-74 million for 4Q 2023 and $256-258 million for FY 2023. The company increased its FY 2024 and 2025 total revenue guidance to more than $320 million and $370 million, respectively. FY 2024 net income is expected to exceed $60 million, and adjusted EBITDA is expected to be $85 million. ADMA also announced new growth opportunities targeting manufacturing and a new pipeline hyperimmune globulin to advance during 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.32%
Tags
Rhea-AI Summary
ADMA Biologics, Inc. (Nasdaq: ADMA) replaces existing credit facility with a new $135 million credit facility, reducing total debt by 15%. The company used the proceeds to repay all obligations under the prior credit facility, aiming to support rapid earnings growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
none
ADMA Biologics, Inc.

Nasdaq:ADMA

ADMA Rankings

ADMA Stock Data

2.20B
223.72M
2.59%
76.26%
3.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
RAMSEY

About ADMA

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.